Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy.
Mycobacteria other than tuberculosis infections in patients taking various tumour necrosis factor (TNF)-alpha inhibitors have been reported in the literature. We describe sporotrichoid spread of Mycobacterium marinum in a man with Crohn's disease treated with infliximab. After starting ethambutol and rifampicin and discontinuing infliximab, a worsening appeared. M. marinum infection may have a potential local spread and systemic dissemination in patients treated with TNF-alpha inhibitors.
Ramos
José M
JM
Infectious Diseases Unit, Internal Medicine Department, Hospital General Universitario de Elche, Alicante, Spain.
García-Sepulcre
Mariana F
MF
Digestive Section, Hospital General Universitario de Elche, Alicante, Spain.
Rodríguez
Juan C
JC
Microbiology Section, Hospital General Universitario de Elche, Alicante, Spain.
Padilla
Sergio
S
Infectious Diseases Unit, Internal Medicine Department, Hospital General Universitario de Elche, Alicante, Spain.
Gutiérrez
Félix
F
Infectious Diseases Unit, Internal Medicine Department, Hospital General Universitario de Elche, Alicante, Spain.
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy*; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis* / Q000382:microbiology; D019910:Mycobacterium marinum / Q000302:isolation & purification*; D012293:Rifampin / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D004977:Ethambutol; D012293:Rifampin